Patent Expert: It's Not Over For Gilead, Still Has Strong Defense Against Merck

In a new report, Citi analyst Robyn Karnauskas discusses the Gilead Sciences, Inc. (NASDAQ: GILD)/Merck & Co., Inc. (NYSE: MRK) ...